Volume 17, Issue 4 (December-2025 2025)                   Iranian Journal of Blood and Cancer 2025, 17(4): 27-35 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Srivastava S, Nag R, Eba A, Raza S T. Mechanisms of Resistance in CML and the Emerging Role of Asciminib and Other Next-Generation Inhibitors. Iranian Journal of Blood and Cancer 2025; 17 (4) :27-35
URL: http://ijbc.ir/article-1-1830-en.html
Mechanisms of Resistance in CML and the Emerging Role of Asciminib and Other Next-Generation Inhibitors
Sanchita Srivastava *1 , Riya Nag1 , Ale Eba1 , Syed Tasleem Raza1
1- Department of Biotechnology, Era’s Lucknow Medical College and Hospital Lucknow, India.
Abstract:   (251 Views)
Chronic myeloid leukemia (CML) is a myeloproliferative disorder driven by the BCR-ABL1 fusion gene that confers constitutive tyrosine kinase activity. Although tyrosine kinase inhibitors (TKIs) have revolutionized CML therapy, resistance remains a major clinical challenge, primarily due to kinase domain mutations, leukemic stem cell persistence, and compensatory signalling pathways. Asciminib, a novel allosteric STAMP inhibitor targeting the ABL myristoyl pocket, introduces a distinct mechanism to overcome resistance associated with ATP-site mutations such as T315I. This review highlights the molecular basis of TKI resistance, mechanisms of BCR-ABL1–dependent and –independent resistance, and emerging strategies including combination therapy, degraders, and immunotherapeutic approaches. Real-world data and clinical trials demonstrate asciminib’s efficacy and favorable safety in multi-resistant CML. The future of CML management lies in precision-driven multimodal therapy aimed at eradicating leukemic stem cells and achieving treatment-free remission.
Keywords: Chronic Myeloid Leukemia, Asciminib, BCR-ABL1, Tyrosine Kinase Inhibitors, Drug Resistance
Full-Text [PDF 623 kb]   (301 Downloads)    
: Review Article | Subject: Adults Hematology & Oncology
Received: 2025/11/7 | Accepted: 2025/12/17 | Published: 2025/12/30
References
1. Vitus OC. Advancements in targeted therapies for chronic myeloid leukemia: current perspectives. Hematological Insights & Blood Disorders. 2023;1(2):1-3. doi:10.64347/3066-3393/hibd.009 [DOI:10.64347/3066-3393/HIBD.009]
2. Lai HR, Wu QM, Yang YZ, Li J. Recent advance of newly therapy for chronic myeloid leukemia with BCR-ABL T315I mutation. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2023;31(5):1579-83.
3. Zhang Y, Nadworny S, Liu S, Zhang S, Ye E, Narasimhan N, et al. Discovery of potent and selective next-generation pan-BCR-ABL inhibitors for the treatment of CML and Ph+ ALL. Blood. 2023;142:1428. [DOI:10.1182/blood-2023-172982]
4. Das DK. ALLG CML13 Ascend-CML study unveils success with asciminib. Oncology Times. 2024. doi:10.1097/01.cot.0001005180.51220.7b [DOI:10.1097/01.COT.0001005180.51220.7b]
5. Padala S, Cortes J. Asciminib in chronic myeloid leukemia: a STAMP for expedited delivery? Haematologica. 2023;108(11):2913. [DOI:10.3324/haematol.2022.282361]
6. Okabe S, Moriyama M, Gotoh A. Characterization of asciminib-resistant Philadelphia chromosome-positive cells. World J Oncol. 2024;15(2):319. [DOI:10.14740/wjon1818]
7. Okamoto N, Yagi K, Imawaka S, Takaoka M, Aizawa F, Niimura T, et al. Asciminib, a novel allosteric inhibitor of BCR-ABL1, shows synergistic effects when used in combination with imatinib with or without drug resistance. Pharmacol Res Perspect. 2024;12(4):e1214. [DOI:10.1002/prp2.1214]
8. Nardi V, Schwieterman J, Kincaid Z, Brunner AM, Reyes M, Griffin GK, et al. A novel BCR::ABL1 rearrangement harboring the gatekeeper mutation drives hyper-kinase activity conferring resistance to ponatinib and asciminib combination therapy. Blood. 2024;144:4541. [DOI:10.1182/blood-2024-211279]
9. Assanto GM, Scalzulli E, Breccia M. Asciminib in chronic myeloid leukemia. Drugs Today. 2022;58(10):479-89. doi:10.1358/dot.2022.58.10.3441853 [DOI:10.1358/dot.2022.58.10.3441853]
10. Leyte-Vidal A, Garrido Ruiz D, DeFilippis R, Leske IB, Rea D, Phan S, et al. BCR::ABL1 kinase N-lobe mutants confer moderate to high degrees of resistance to asciminib. Blood. 2024;144(6):639-45. [DOI:10.1182/blood.2023022538]
11. Onodera K, Fukuhara N. The evolution of the treatment of chronic myelogenous leukemia. Gan To Kagaku Ryoho. 2022;49(10):1035-9.
12. El-Tanani M, Nsairat H, Matalka II, Lee YF, Rizzo M, Aljabali AA, et al. The impact of the BCR-ABL oncogene in the pathology and treatment of chronic myeloid leukemia. Pathol Res Pract. 2024;254:155161. [DOI:10.1016/j.prp.2024.155161]
13. Bracco E, Ali MS, Magnati S. The paradigm of targeting an oncogenic tyrosine kinase. Adv Precision Med Oncol. 2021;231. [DOI:10.5772/intechopen.97528]
14. Zhou X, Li A, Kong D, Shi Y, Zhang P, Shan N. The silent players: atypical BCR-ABL isoforms as biomarkers and therapeutic hurdles in CML pathogenesis. Oncol Rep. 2025;54(6):162. [DOI:10.3892/or.2025.8995]
15. Khalid R, Riasat S. Molecular pathogenesis and treatment strategies of chronic myeloid leukemia (CML). Sudan J Med Sci. 2023;18(4):525-38. [DOI:10.18502/sjms.v18i4.14741]
16. Tan Y, Huang Z, Wang X, Dai H, Jiang G, Feng W. A novel fusion circular RNA F-circBA1 derived from the BCR-ABL fusion gene displayed an oncogenic role in chronic myeloid leukemia cells. Bioengineered. 2021;12(1):4816-27. [DOI:10.1080/21655979.2021.1957749]
17. Baykal S, Voldoire M, Desterke C, Sorel N, Cayssials E, Johnson-Ansah H, et al. ENOX2 NADH oxidase: a BCR-ABL1-dependent cell surface and secreted redox protein in chronic myeloid leukemia. Turk J Hematol. 2023;40(2):101. [DOI:10.4274/tjh.galenos.2023.2022-0339]
18. Shyam Sunder S, Sharma UC, Pokharel S. Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management. Signal Transduction and Targeted Therapy. 2023 Jul 7;8(1):262. [DOI:10.1038/s41392-023-01469-6]
19. Alves R, Gonçalves AC, Rutella S, Almeida AM, De Las Rivas J, Trougakos IP, et al. Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia - from molecular mechanisms to clinical relevance. Cancers (Basel). 2021;13(19):4820. [DOI:10.3390/cancers13194820]
20. Combarel D, Dousset L, Bouchet S, Ferrer F, Tetu P, Lebbe C, et al. Tyrosine kinase inhibitors in cancers: treatment optimization - Part I. Crit Rev Oncol Hematol. 2024;199:104384. [DOI:10.1016/j.critrevonc.2024.104384]
21. Sweeney PL, Suri Y, Basu A, Koshkin VS, Desai A. Mechanisms of tyrosine kinase inhibitor resistance in renal cell carcinoma. Cancer Drug Resist. 2023;6(4):858. [DOI:10.20517/cdr.2023.89]
22. Sekino Y, Teishima J, Liang G, Hinata N. Molecular mechanisms of resistance to tyrosine kinase inhibitor in clear cell renal cell carcinoma. Int J Urol. 2022;29(12):1419-28. [DOI:10.1111/iju.15042]
23. Tian Y, Lei Y, Fu Y, Sun H, Wang J, Xia F. Molecular mechanisms of resistance to tyrosine kinase inhibitors associated with hepatocellular carcinoma. Curr Cancer Drug Targets. 2022;22(6):454-62. [DOI:10.2174/1568009622666220330151725]
24. Kobayashi K, Tan AC. Unraveling the impact of intratumoral heterogeneity on EGFR tyrosine kinase inhibitor resistance in EGFR-mutated NSCLC. Int J Mol Sci. 2023;24(4):4126. [DOI:10.3390/ijms24044126]
25. Parsons HA, Messer C, Santos K, Danysh BP, Hughes ME, Patel A, et al. Genomic mechanisms of resistance to tyrosine kinase inhibitors (TKIs) in HER2+ metastatic breast cancer (HER2+ MBC). Cancer Res. 2023;83(7 Suppl):3874. [DOI:10.1158/1538-7445.AM2023-3874]
26. Yoshimaru R, Minami Y. Genetic landscape of chronic myeloid leukemia and a novel targeted drug for overcoming resistance. Int J Mol Sci. 2023;24(18):13806. [DOI:10.3390/ijms241813806]
27. Gupta P, Ashar YV, Ashby CR Jr, Lin L, Chen ZS. The oncogenic protein, breakpoint cluster (BCR)-Abelson kinase (ABL) and chronic myelocytic leukemia (CML): insight into the drug resistance mechanisms and approaches for targeting BCR-ABL in CML.
28. Tan Y, Zhang L, Zhu G, Yang Y, Guo W, Chen L, et al. BCR/ABL1ΔE7-8-9 isoform contributes to tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Hematol Oncol. 2022;40(5):1067-75. [DOI:10.1002/hon.3040]
29. Lahmouad M, Rachid Z, Bellemrrabet R, Zerrouk J, Goh KW, Bouyahya A, et al. Mechanisms and signaling pathways of tyrosine kinase inhibitor resistance in chronic myeloid leukemia: a comprehensive review. Leuk Res Rep. 2025;100533. [DOI:10.1016/j.lrr.2025.100533]
30. Al Hamad M. Contribution of BCR-ABL molecular variants and leukemic stem cells in response and resistance to tyrosine kinase inhibitors: a review. F1000Res. 2022;10:1288. https://doi.org/10.12688/f1000research.74570.1 [DOI:10.12688/f1000research.74570.2]
31. Bica V, Venafra V, Massacci G, Graziosi S, Gualdi S, Minnella G, et al. Phosphoproteomics reveals novel BCR::ABL1-independent mechanisms of resistance in chronic myeloid leukemia. bioRxiv. 2025;2025-01. [DOI:10.1101/2025.01.08.631869]
32. Soverini S. Resistance mutations in CML and how we approach them. Hematology (Am Soc Hematol Educ Program). 2023;2023(1):469-75. [DOI:10.1182/hematology.2023000447]
33. Busch C, Mulholland T, Zagnoni M, Dalby M, Berry C, Wheadon H. Overcoming BCR::ABL1 dependent and independent survival mechanisms in chronic myeloid leukaemia using a multi-kinase targeting approach. Cell Commun Signal. 2023;21(1):342. [DOI:10.1186/s12964-023-01363-2]
34. Barnes EJ, Eide CA, Kaempf A, Bottomly D, Romine KA, Wilmot B, et al. Secondary fusion proteins as a mechanism of BCR::ABL1 kinase-independent resistance in chronic myeloid leukaemia. Br J Haematol. 2023;200(3):323-8. [DOI:10.1111/bjh.18515]
35. Sears D, Luong P, Yuan M, Nteliopoulos G, Man YK, Melo JV, Basu S. Functional phosphoproteomic analysis reveals cold-shock domain protein A to be a Bcr-Abl effector-regulating proliferation and transformation in chronic myeloid leukemia. Cell Death & Disease. 2010 Nov;1(11):e93. [DOI:10.1038/cddis.2010.72]
36. Mancini M, De Santis S, Monaldi C, Castagnetti F, Lonetti A, Bruno S, et al. Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors. Front Oncol. 2022;12:901132. [DOI:10.3389/fonc.2022.901132]
37. Baykal-Köse S, Acikgoz E, Yavuz AS, Gönül Geyik Ö, Ateş H, Sezerman OU, et al. Adaptive phenotypic modulations lead to therapy resistance in chronic myeloid leukemia cells. PLoS One. 2020;15(2):e0229104. [DOI:10.1371/journal.pone.0229104]
38. Awad SA, Dufva O, Klievink J, Karjalainen E, Ianevski A, Pietarinen P, et al. Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemia. Cell Rep Med. 2024;5(5). [DOI:10.1016/j.xcrm.2024.101521]
39. Amarante-Mendes GP, Rana A, Datoguia TS, Hamerschlak N, Brumatti G. BCR-ABL1 tyrosine kinase complex signaling transduction: challenges to overcome resistance in chronic myeloid leukemia. Pharmaceutics. 2022;14(1):215. [DOI:10.3390/pharmaceutics14010215]
40. Duggirala KB, Lee Y, Lee K. Chronicles of EGFR tyrosine kinase inhibitors: targeting EGFR C797S containing triple mutations. Biomol Ther. 2021;30(1):19. [DOI:10.4062/biomolther.2021.047]
41. Tfayli A, Mohty R. EGFR tyrosine kinase inhibitors in non-small cell lung cancer: treatment paradigm, current evidence, and challenges. Tumori J. 2021;107(5):376-84. [DOI:10.1177/0300891620968138]
42. Gad MM, Abdelwaly A, Helal MA. Structural basis for the selectivity of 3rd generation EGFR inhibitors: a molecular dynamics study. J Biomol Struct Dyn. 2023;41(13):6134-44. [DOI:10.1080/07391102.2022.2103028]
43. Heppner DE. Design and development of mutant EGFR inhibitors from a structural perspective. Indian J Biochem Biophys. 2023;60(9):645-50.
44. De Novellis D, Cacace F, Caprioli V, Wierda WG, Mahadeo KM, Tambaro FP. The TKI era in chronic leukemias. Pharmaceutics. 2021;13(12):2201. [DOI:10.3390/pharmaceutics13122201]
45. Zhou LY. Research advance of BCR-ABL mutation and the efficacy of second and third generation TKI in chronic myeloid leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2023;31(2):585-8.
46. Azimian F, Dastmalchi S. Recent advances in structural modification strategies for lead optimization of tyrosine kinase inhibitors to explore novel anticancer agents. Curr Med Chem. 2023;30(24):2734-61. [DOI:10.2174/0929867329666220920092908]
47. Okafor CE, Egwuatu EC, Owosagba VA, Njei T, Adeyemi BI, Onuche PU, et al. From bench to bedside: medicinal chemistry strategies in the development of kinase inhibitors for cancer therapy. J Cancer Tumor Int. 2025;15(2):79-96. [DOI:10.9734/jcti/2025/v15i2294]
48. Besch A, Marsiglia WM, Mohammadi M, Zhang Y, Traaseth NJ. Gatekeeper mutations activate FGF receptor tyrosine kinases by destabilizing the autoinhibited state. Proc Natl Acad Sci U S A. 2023;120(8):e2213090120. [DOI:10.1073/pnas.2213090120]
49. Lai HR, Wu QM, Yang YZ, Li J. Recent advance of newly therapy for chronic myeloid leukemia with BCR-ABL T315I mutation. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2023;31(5):1579-83.
50. Ahn SM, Kim DW. KF1601, a novel orally bioavailable inhibitor of BCR-ABL1 T315I without inducing thrombotic microangiopathy. Blood. 2023;142:6352. [DOI:10.1182/blood-2023-190891]
51. Milojkovic D, Blijlevens N, Kwong YL, Zaidi U, Castagnetti F, Gallipoli P, et al. Real-world effectiveness of asciminib in patients with chronic myeloid leukemia harboring the T315I mutation: a global chart review study. Blood. 2023;142:4541. [DOI:10.1182/blood-2023-181937]
52. Meza CP, Salizzato V, Calistri E, Basso M, Zavatti M, Marmiroli S, et al. Critical role of protein kinase CK2 in chronic myeloid leukemia cells harboring the T315I BCR::ABL1 mutation. Int J Biol Macromol. 2025;286:138305. [DOI:10.1016/j.ijbiomac.2024.138305]
53. Mian AA, Haberbosch I, Khamaisie H, Agbarya A, Pietsch L, Eshel E, et al. Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native and resistant mutants. Ann Hematol. 2021;100(8):2023-9. [DOI:10.1007/s00277-020-04357-z]
54. Hughes TP, White DL, Yeung DT. Asciminib for Philadelphia chromosome-positive leukemias. Haematologica. 2025;110(10):2273. [DOI:10.3324/haematol.2024.286798]
55. Réa D, Hughes TP. Development of asciminib, a novel allosteric inhibitor of BCR-ABL1. Crit Rev Oncol Hematol. 2022;171:103580. [DOI:10.1016/j.critrevonc.2022.103580]
56. Shanmuganathan N, Hughes TP. Asciminib for chronic myeloid leukaemia: next questions. Br J Haematol. 2022;199(3):322-31. [DOI:10.1111/bjh.18323]
57. PharmaNews. PharmaNews. 2023;9(1):29-30. doi:10.1159/000529575 [DOI:10.1159/000529575]
58. Breccia M, Rossi AR, Martino B, Abruzzese E, Annunziata M, Binotto G, et al. ASCIMINIB Italian managed access program: efficacy profile in heavily pre-treated CML patients. HemaSphere. 2022;6:607-8. [DOI:10.1097/01.HS9.0000845732.28959.a9]
59. Chung J, Ariyoshi T, Yoneda T, Kagawa Y, Kawakita Y, Maki A. Pharmacological and clinical profile of asciminib hydrochloride. Nihon Yakurigaku Zasshi. 2023;158(3):273-81. [DOI:10.1254/fpj.22156]
60. Yılmaz R, Eşkazan AE. Breaking the mold: asciminib as standard of care in CML. Future Oncol. 2023;19(8):545-7. [DOI:10.2217/fon-2023-0095]
61. Atallah EL, Sadek I, Wei D, Latremouille-Viau D, Rossi C, Damon A, et al. Treatment with asciminib as second line after one prior TKI in chronic-phase CML: a chart review study. Blood. 2024;144:3812. [DOI:10.1182/blood-2024-193201]
62. Khadadah FM, Cerquozzi S, Olney HJ, Fraga C, Dudebout J, Xenocostas A, et al. Canadian real-world experience of asciminib in heavily pre-treated CML patients. Leuk Res. 2023;133:107374. [DOI:10.1016/j.leukres.2023.107374]
63. Khanna A, Small H, Lutchman D, Schofield P. ASC4REAL: efficacy and tolerability comparison between ASCEMBL study and real-world experience.
64. Breccia M, Russo Rossi A, Giai V, Martino B, Fava C, Annunziata M, et al. Real-world efficacy profile of asciminib in multi-resistant CML population. HemaSphere. 2023;7:e55133e1. [DOI:10.1097/01.HS9.0000969648.55133.e1]
65. Chee L, Lee N, Grigg A, Chen M, Schwarer A, Szer J, et al. Clinical outcomes of CML patients taking asciminib through a Managed Access Programme in Australia. Intern Med J. 2024;54(7):1214-8. [DOI:10.1111/imj.16446]
66. Frustaci AM, Deodato M, Zamprogna G, Cairoli R, Montillo M, Tedeschi A. Next generation BTK inhibitors in CLL: evolving challenges and opportunities. Cancers (Basel). 2023;15(5):1504. [DOI:10.3390/cancers15051504]
67. Zhong J, Xiao R, Xie W, Chen M, Chen X, Wang H, Liu Y, Gao Q, Wang X, Wang Z, Chen Q. Abstract CT056: Development of a novel next-generation RET inhibitor. Cancer Research. 2024 Apr 5;84(7_Supplement):CT056. [DOI:10.1158/1538-7445.AM2024-CT056]
68. Oya Y, Imaizumi K, Mitsudomi T. The next-generation KRAS inhibitors: what comes after sotorasib and adagrasib? Lung Cancer. 2024;194:107886. [DOI:10.1016/j.lungcan.2024.107886]
69. Roa P, Foglizzo V, Harada G, Repetto M, Kulick A, de Stanchina E, et al. Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents. Br J Cancer. 2024;131(3):601-10. [DOI:10.1038/s41416-024-02760-1]
70. Lavaud P, Dumont C, Thibault C, Albiges L, Baciarello G, Colomba E, et al. Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer. Ther Adv Med Oncol. 2020;12:1758835920978134. [DOI:10.1177/1758835920978134]
71. Patel AA, Odenike O. The next generation of JAK inhibitors: an update on fedratinib, momelotonib, and pacritinib. Curr Hematol Malig Rep. 2020;15(6):409-18. [DOI:10.1007/s11899-020-00596-z]
72. Ihlamur M, Akgül B, Zengin Y, Korkut ŞV, Kelleci K, Abamor EŞ. The mTOR signaling pathway and mTOR inhibitors in cancer: next-generation inhibitors and approaches. Curr Mol Med. 2024;24(4):478-94. [DOI:10.2174/1566524023666230509161645]
Add your comments about this article : Your username or Email:
CAPTCHA
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2026 All Rights Reserved | Iranian Journal of Blood and Cancer

Designed & Developed by : Yektaweb